echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Lancet rheumat: Targeting the proliferation of synovial fibroblasts, a new treatment direction for rheumatoid arthritis?

    Lancet rheumat: Targeting the proliferation of synovial fibroblasts, a new treatment direction for rheumatoid arthritis?

    • Last Update: 2021-03-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At present, rheumatoid arthritis therapy mainly targets immune inflammation, which may have a ceiling effect.


    Immune Seliciclib is an oral cyclin-dependent kinase inhibitor that can inhibit the proliferation of synovial fibroblasts.


    The TRAFIC study is a non-randomized, open-label, dose-exploratory phase 1b/2a clinical trial.


    diagnosis

    Basic patient characteristics

    Basic patient characteristics

    From October 8, 2015 to August 15, 2017, 37 patients were screened , and 15 of them were divided into 5 cohorts to receive Seliciclib treatment (200 mg, 400 mg, 600 mg, 800 mg, or 1000 mg orally; 3 patients per dose level).


    Screening

    Dose-related toxicity

    Dose-related toxicity

    The maximum tolerated dose of Seliciclib is 400 mg , and the estimated dose-limiting toxicity probability at this dose level is approximately 0.


    The maximum tolerated dose of Seliciclib is 400 mg The maximum tolerated dose of Seliciclib is 400 mg is consistent with the known safety issues of Seliciclib

    Changes of DAS28-CRP score before and after treatment

    Changes of DAS28-CRP score before and after treatment

    In addition, during the trial period, 65 non-severe adverse events occurred, of which 50 were considered to be related to treatment .


    There were 65 non-severe adverse events, 50 of which were considered related to treatment

    Treatment-related adverse reactions

    Treatment-related adverse reactions

    In summary, the maximum tolerated dose of Seliciclib for TNF-blocked rheumatoid arthritis has been established (400 mg) .


    The maximum tolerated dose of Seliciclib for refractory rheumatoid arthritis with TNF blockade has been determined (400 mg)

    Original source:

    Original source:

    Arthur G Pratt, et al.


    org/10.
    1016/S2665-9913(21)00061-8" target="_blank" rel="noopener">Targeting synovial fibroblast proliferation in rheumatoid arthritis ( TRAFIC): an open-label, dose-finding, phase 1b trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.